Public Employees Retirement System of Ohio lowered its stake in Innoviva Inc (NASDAQ:INVA) by 13.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 58,213 shares of the biotechnology company’s stock after selling 9,070 shares during the quarter. Public Employees Retirement System of Ohio owned about 0.06% of Innoviva worth $848,000 at the end of the most recent quarter.
Other hedge funds also recently bought and sold shares of the company. Quantamental Technologies LLC acquired a new stake in Innoviva in the second quarter worth about $70,000. Valeo Financial Advisors LLC acquired a new stake in Innoviva in the 2nd quarter valued at about $100,000. Bank of Montreal Can lifted its holdings in Innoviva by 175.4% in the 2nd quarter. Bank of Montreal Can now owns 10,167 shares of the biotechnology company’s stock valued at $147,000 after acquiring an additional 6,475 shares during the last quarter. National Asset Management Inc. acquired a new stake in Innoviva in the 1st quarter valued at about $152,000. Finally, Fox Run Management L.L.C. acquired a new stake in Innoviva in the 2nd quarter valued at about $158,000. 75.60% of the stock is owned by institutional investors and hedge funds.
NASDAQ INVA traded up $0.06 on Friday, reaching $11.03. The company’s stock had a trading volume of 789,242 shares, compared to its average volume of 458,484. Innoviva Inc has a twelve month low of $10.76 and a twelve month high of $20.54. The company has a debt-to-equity ratio of 1.57, a quick ratio of 42.50 and a current ratio of 42.50. The stock has a market cap of $1.12 billion, a PE ratio of 3.12 and a beta of 1.51. The firm’s 50 day moving average is $11.37 and its two-hundred day moving average is $13.34.
INVA has been the subject of a number of research analyst reports. TheStreet downgraded shares of Innoviva from a “b-” rating to a “c+” rating in a report on Thursday, August 8th. ValuEngine downgraded shares of Innoviva from a “sell” rating to a “strong sell” rating in a report on Friday, July 26th. BidaskClub downgraded shares of Innoviva from a “sell” rating to a “strong sell” rating in a report on Saturday. Finally, Zacks Investment Research raised shares of Innoviva from a “sell” rating to a “buy” rating and set a $13.00 price target for the company in a report on Tuesday.
Innoviva Company Profile
Innoviva, Inc engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a long-acting beta2 agonist (LABA), vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate (FF); ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA and LABA.
Want to see what other hedge funds are holding INVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Innoviva Inc (NASDAQ:INVA).
Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.